| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg |
|
||
| 250mg |
|
||
| Other Sizes |
Purity: ≥98%
LY2979165, a novel and potent mGlu2 agonist being developed as an anti-depressant drug candidate, has potential usefulness in the treatment of bipolar disorder. LY2979165 is being developed by Eli Lilly, and is currently in clinical trials.
| Targets |
Metabotropic glutamate receptor 2 (mGlu2) agonist (EC50 = 7.57 nM in human cortical brain tissue) [1]
|
|---|---|
| ln Vitro |
A GTP-γ[35S] functional binding assay was used to evaluate the pharmacology of 2812223 (active metabolite of LY2979165) in human cortical brain tissue samples, where it was found to be a partial mGlu2 agonist with an in vitro EC50 value of 7.57 nM. [1]
|
| ln Vivo |
In vivo, LY2979165 reduces the BOLD phMRI signal caused by ketamine [2].
LY2979165 showed activity in the phencyclidine-evoked ambulation model in rats, an animal model of psychosis sensitive to mGlu2 receptor activation. [1] |
| Enzyme Assay |
A GTP-γ[35S] functional binding assay was performed using human cortical brain tissue samples to assess the agonist activity of 2812223 at mGlu2 receptors. The assay measured the functional response indicative of receptor activation, and the EC50 was determined to be 7.57 nM. [1]
|
| Animal Protocol |
In a rat model of psychosis (phencyclidine-evoked ambulation model), LY2979165 was administered to evaluate its antipsychotic-like activity. [1]
|
| ADME/Pharmacokinetics |
After oral administration of LY2979165, the drug is rapidly absorbed systemically and converted into the active ingredient 2812223, and the concentration of 2812223 can be detected in plasma within 30 minutes. After once-daily administration, the plasma pharmacokinetics of 2812223 are approximately linear, with very low accumulation. Within 24 hours, 44% to 62% of 2812223 is excreted in urine. Food has no significant effect on the pharmacokinetics of LY2979165 or 2812223. 2812223 can be detected in cerebrospinal fluid, and its cerebrospinal fluid exposure is approximately 2% to 6% of the plasma exposure. The mean terminal elimination half-life (t1/2) of 2812223 is approximately 9 to 17 hours for each dose group. [1]
|
| Toxicity/Toxicokinetics |
The most common adverse events during treatment in healthy subjects were dizziness, vomiting, nausea, somnolence, and headache. Vomiting was a dose-limiting adverse event after a single dose, but higher doses were tolerated with a 14-day dose titration regimen. No serious adverse events were reported. No clinically relevant changes were observed in hematology, clinical chemistry, vital signs, urinalysis, or electrocardiogram measurements. [1]
|
| References |
|
| Additional Infomation |
LY2979165 is an alanine prodrug of the selective orthotopic mGlu2 receptor agonist 2812223. It is being developed as a potential antipsychotic. Clinical studies are being conducted primarily in healthy male subjects (predominantly Asian) to evaluate its safety, tolerability, pharmacokinetics, and pharmacodynamics. These studies support further clinical evaluation of the use of LY2979165 in mental illness. [1]
|
| Molecular Formula |
390.42
|
|---|---|
| Molecular Weight |
C13H22N6O6S
|
| Exact Mass |
390.132
|
| CAS # |
1311385-32-6
|
| PubChem CID |
66577008
|
| Appearance |
White to off-white solid powder
|
| LogP |
0.702
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
11
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
26
|
| Complexity |
577
|
| Defined Atom Stereocenter Count |
6
|
| SMILES |
C[C@@H](C(=O)N[C@]1(C[C@H]([C@@H]2[C@H]1[C@H]2C(=O)O)SC3=NC=NN3)C(=O)O)N.N.O
|
| InChi Key |
FICWTZOQUXUYOK-AHKKVLALSA-N
|
| InChi Code |
InChI=1S/C13H17N5O5S.H3N.H2O/c1-4(14)9(19)17-13(11(22)23)2-5(24-12-15-3-16-18-12)6-7(8(6)13)10(20)21;;/h3-8H,2,14H2,1H3,(H,17,19)(H,20,21)(H,22,23)(H,15,16,18);1H3;1H2/t4-,5+,6-,7-,8-,13-;;/m0../s1
|
| Chemical Name |
ammonium (1R,2S,4R,5R,6R)-4-((4H-1,2,4-triazol-3-yl)thio)-2-((S)-2-aminopropanamido)-2-carboxybicyclo[3.1.0]hexane-6-carboxylate hydrate
|
| Synonyms |
LY2979165; LY-2979165; LY 2979165.
IUPAC/Chemical Name: ammonium (1R,2S,4R,5R,6R)-4-((4H-1,2,4-triazol-
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
H2O : ≥ 50 mg/mL (~128.07 mM)
DMSO : ~1 mg/mL (~2.56 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 0.1 mg/mL (0.26 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 1.0 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. Solubility in Formulation 2: 50 mg/mL (128.07 mM) in PBS (add these co-solvents sequentially from left to right, and one by one), clear solution; with ultrasonication. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA